Fig. 2
Experimental design to test the hypothesis. First, in vitro (a): determination of the biocompatibility of the synthesized nanoconjugate. Ex vivo test (b): testing the specificity of anti-CHO-MNPs nanoconjugate by incubation of nanoplatform on fixed brain slices from 5XFAD transgenic mice. In vivo studies (c): the nanoplatform will be injected intravenously or by alternative routes as intranasal delivery/external magnetic field application, and its effectiveness (targeting) will be evaluated by MRI